Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Photobiomodulation is an effective and safe treatment for increasing hair growth in people with hair loss.

This review discusses the causes and treatments of hirsutism, emphasizing identifying potentially life-threatening pathologies, but it reports no new clinical results.

Birth control pills and anti-androgen medications help manage hair growth, acne, and hair loss in women with PCOS.

This study found that lifestyle interventions improved body composition, hyperandrogenism, and insulin resistance in women with PCOS, but did not affect glucose tolerance, lipid profiles, or clinical reproductive outcomes.

This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.

This study found that the ovarian stromal area to total ovarian area ratio alone is not a strong predictor of biochemical hyperandrogenism in Thai women with PCOS, but combining it with clinical hyperandrogenism improves prediction.

This review discusses recent advances in hair follicle research, highlighting therapeutic and cosmetic applications, but reports no new study results.

This guideline from the Endocrine Society recommends using the Rotterdam criteria for diagnosing polycystic ovary syndrome and outlines first-line treatments, emphasizing hormonal contraceptives and lifestyle intervention.

This study demonstrated that minoxidil-encapsulated PLLGA nanoparticles significantly increased minoxidil delivery to hair follicles compared to a minoxidil aqueous solution in mice.

This article provides industry updates on stem cell research and regenerative medicine from December 2019 and reports no new research findings.

This case report describes a 48-year-old woman with a history of PCOS and chemotherapy-induced menopause who was found to have a rare ovarian steroid cell tumor causing postmenopausal hyperandrogenism.

This investigation found that certain supplements, particularly whey protein isolate, growth hormones, and anabolic steroids, can negatively impact hair loss by affecting biochemical pathways.

This study summarizes current knowledge on the role of creatine in the human body, its applications in supplementation, and its impact on muscle mass, especially noting that animal-based foods are primary dietary sources and that women may experience health benefits from supplementation.

This review discusses the potential benefits of a nutraceutical with biooptimized botanical extracts for treating hair loss and reports no new clinical results; ongoing studies aim to validate its efficacy.

This study identified 12 potential candidate biomarkers associated with hair loss by analyzing the differential expression of genes, suggesting possible therapeutic targets for alopecia.

This narrative review explores how exosomes and cell culture-conditioned media are becoming key players in the cosmetic industry for skin rejuvenation and prejuvenation, emphasizing their multifunctional topical benefits and potential future applications.

This study examined connections between bioelements like Zn, Cu, and Mn in serum and bone tissue and hormone concentrations in men with and without erectile dysfunction, highlighting potential relationships that may help explain ED's etiology.

This study developed nanoliposomes embedding AR-PROTAC and NFKBIZ siRNA to target androgen receptors and reduce oxidative stress, which improved the follicular microenvironment and enhanced hair regrowth in androgenetic alopecia, suggesting a promising multi-target therapeutic strategy.

In this study, researchers developed a promising transdermal agent using Triton X-100-modified polyethyleneimine that successfully delivered genetic material to hair follicle cells in mice, potentially alleviating hair loss due to androgenetic alopecia by promoting cell proliferation and inhibiting apoptosis.

This review discusses the current understanding of androgen biosynthesis, mechanisms of action, and their roles in human biology, as well as related congenital and acquired disorders, but it reports no new research findings.

This study reported that the compound (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile effectively stimulated hair growth in mice and reduced sebum production in hamsters.

This study used a newly validated method to find that one-year finasteride treatment resulted in no significant differences in urinary androgen and prostaglandin levels between male pattern baldness patients and normal controls.

This commentary reviews potential dietary and mineral influences on androgenetic alopecia and suggests considering a diet low in cholesterol and glycaemic index with improved glucose control and magnesium fortification, without new clinical results.

This study generated FGF5-knockout Dorper sheep using the CRISPR/Cas9 system, resulting in significantly increased fine-wool and active hair-follicle density, and explored downstream signaling pathways for potential applications in androgen alopecia treatment.

This study found that androgen signaling has complex effects on bone formation in male AR3.6-transgenic mice, with varying impacts based on the embryonic lineage of cells.

This study suggests that DHT may have a less potent effect on the prostate compared to testosterone while maintaining safety and similar effects on erythropoiesis and lipids.

This study reports that new compounds with anti-androgenic effects were found to counteract testosterone in animals without significant estrogenic activity, indicating potential for managing androgen-related conditions.

This review discusses the regulation of hair growth, causes of excessive androgen secretion, and current safe solutions for hyperandrogenism manifestations in women but reports no new clinical results.

This study suggests that policosanol may prevent androgenetic alopecia in mice by regulating hormone levels and suppressing premature hair follicle entry into the regression phase.

In this study focused on reproductive-aged women assessed for polycystic ovary syndrome under NIH 1990 criteria, only 15.4% with menstrual dysfunction required androgen measurements, and just one-quarter of these showed elevated androgen levels.